Buy Cabazitaxel|183133-96-2|DNA damage|from supplier chembestbuy.com|Research only

Home

Add Favorites

Search Product

Live Chat

E-mail

Pharmacology

Inhibitors

Receptors

Hedgehog Signaling Pathway

Research Area

Cardiovascular System

Product Type

Vitamin D series compounds

Toxins

　 More +

Browse Alphabetically by Name

ALL	A	B	C	D	E	F
G	H	I	J	K	L	M
N	O	P	Q	R	S	T
U	V	W	X	Y	Z	Others

C13417 Cabazitaxel (183133-96-2)

Catalog No.:	C13417
CAS No.:	183133-96-2
Synonym:	XRP6258; RPR-116258A; taxoid XRP6258
Chemical Name:	(alpha R,beta S)-beta-[[(1,1-dimethylethoxy)carbonyl]amino]-alpha-hydroxy-Benzenepropanoic acid 2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester
Molecular Formula:	C₄₅H₅₇NO₁₄
Molecular Weight:	835.93

Technical Data:

Appearance:
Solubility:	Soluble in DMSO
Purity:	>99%
Storage:	at -20℃ 2 years
Original QC Data:
Shipping Conditions:	Ambient Temp.

Price and Availability of Cabazitaxel:

Size	Price	Stock
10mg	USD	In Stock
25mg	USD	In Stock
50mg	USD	In Stock

Biological Activity:

Cabazitaxel(XRP6258; RPR-116258A) is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).

References:

1. Figg WD 2nd, Figg WD. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. Cancer Biol Ther. 2011 Jan 12;10(12):1233-4.

2. Diéras V, Lortholary A, Laurence V et al. Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study. Eur J Cancer. 2012 Sep 10. [Epub ahead of print]

3. Yap TA, Pezaro CJ, de Bono JS. Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2012 Sep;12(9):1129-36.

View Related Products by Target:

Docetaxel Anhydrous

Decitabine(NSC127716)

Topotecan hydrochloride

Leucovorin calcium(Calcium folinate)

XAV-939(NVP-XAV939)

Roscovitine(CYC202)

SN-38(7-Ethyl-10-hydroxycamptothecin)

CPT-11(Irinotecan hydrochloride)

Carboplatin

Cisplatin(CDDP)

ZM 447439

AZD1152-HQPA(Barasertib)